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Autoinflammation due to homozygous S208 
MEFV mutation
Heterozygous mutations in the MEFV gene disrupting the 
Serine-242 residue in the 14-3-3 binding motif of pyrin cause 
Pyrin-AssociatedAutoinflammation with Neutrophilic Derma-
tosis (PAAND).1–5 We now describe familial autoinflammation 
associated with homozygous Serine-208 mutations in MEFV, the 
second crucial phosphorylation site of the pyrin 14-3-3 binding 
domain.
Two Pakistani boys (IV-1 and IV-2; figure 1A) born of consan-
guineous parents presented aged 12 and 9 years old, respec-
tively, with a systemic autoinflammatory disease characterised 
by a remitting relapsing course over time. Both had recurrent 
fevers with elevated acute phase responses: C-reactive protein 
>100 mg/L (reference range (RR)<20); serum-amyloid-A 
>200 mg/L (RR <10); leucocytosis 92×109/L (RR 4–11; eosin-
ophils 82.4×109/L) and normalisation of these parameters 
in between fever attacks. Both had recurrent oral ulceration, 
intestinal inflammation, transient purpuric rashes (leucocyto-
clastic vasculitis on biopsy), lymphadenopathy (biopsy showed 
mixed lymphocytic, eosinophil infiltrate), hepatosplemonegaly, 
arthralgia and failure to thrive. Patient IV-2 developed pulmo-
nary nodular changes and had a history of sterile cutaneous 
neck abscess at age 5. They had normal complement function 
studies, immunoglobulin levels and negative autoantibodies. 
Bone marrow aspirate for IV-2 showed marked eosinophilia 
(81%) with normal morphology and no malignancy; lymphocyte 
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Figure 1 Family tree, genetic sequencing results, proinflammatory cytokines and pyrin inflammasome activation in patients with homozygous 
p.S208T MEFV mutation. (A) The family tree shows the two affected male siblings and their unaffected sibling from the consanguineous marriage 
of first cousins; segregation of the p.S208T MEFV variant is also shown. (B) Sanger sequencing chromatogram of MEFV gene aligned to reference 
sequence exon 2 of MEFV. Line indicates a homozygous mutation of MEFV at position c.623 (red dashed box) present in both affected patients (IV-1 
and IV-2) and heterozygous in parents (III-1 and III-2) and unaffected sister (IV-3). (C) Serum levels of interleukin (IL)-1β were elevated in IV-1 and 
IV-2 (median 0.26 pg/mL, range 0.16–0.44 pg/mL) compared with healthy controls (median 0 pg/mL, range of 0–0.08 pg/mL, p=0.005) and compared 
with their unaffected parents (III-2 and III-3), unaffected sibling (IV-3) all with WT/p.S208T MEFV genotype (median levels of 0.1 pg/mL, range of 
0.08–0.12 pg/mL, p=0.04). (D) Similar differences were observed for total IL-18 levels that were elevated in IV-1 and IV-2 compared with controls, 
p=0.01 and compared with III-1, III-2 and IV-3, p=0.05. (E) Monocytes from IV-1 and IV-2 constitutively expressed higher levels of FLICA (caspase-1) 
in response to lipopolysaccharide (LPS) (mean 398, SEM 84.63) compared with controls (mean 292.8, SEM 95.49, p=0.001) and when compared with 
heterozygotes for p.S208T MEFV mutation (mean 371.5, SEM 109.7, p=0.01). (F) There was an increased release of IL-1β in monocyte supernatants 
derived from IV-1 and IV-2 following LPS stimulation compared with healthy controls (p=0.001). No significant difference in IL-1β secretion was 
observed between healthy and patient monocytes after ATP and TcdB addition. (G) There was enhanced release of CCL5 in patient derived peripheral 
blood mononuclear cells (PBMC) stimulated with LPS (mean relative CCL-5 levels at 233, SEM 37.29 pg/mL) compared with controls (mean relative 
CCL-5 levels of 126.6, SEM 24.91 pg/mL, p=0.02). Similar differences were observed between groups in CCL-5 release in response to PMA/Ionomycin 
stimulation, p=0.001. Error bars represent medians and range or for in vitro experiments means+SEM  for three biological replicates. P values by 
Student’s t-test or Mann-Whitney U test <0.05 were considered significant. CCL-5, C-C-motif chemokine ligand 5; FLICA, fluorochrome inhibitor of 
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clonality studies were normal. Digital subtraction angiography 
and echocardiography were normal. Routine genetic screening 
for TNFRSF1A, MVK, NLRP3, MEFV exon 10 was wild type. 
Both patients partially responded to corticosteroids, but subse-
quently received treatment with cyclophosphamide, mycophe-
nolate mofetil, methotrexate, azathioprine and antitumour 
necrosis factor alpha therapy. Inflammatory attacks persisted 
despite these therapies.
Whole exome sequencing and homozygosity mapping 
(online supplementary text and table S1) identified a homozy-
gous mutation in exon 2 of MEFV comprising of a G–C substi-
tution at G623 leading to a serine to threonine substitution 
at amino acid position 208 (p.S208T) of the pyrin protein. 
The mutation segregated with disease in a recessive manner 
(figure 1B) and was not detected in 100 Pakistani healthy 
controls.
We observed elevated levels of circulating IL-1β in patients 
with homozygous p.S208T MEFV mutations compared with 
healthy controls, p=0.005 and heterozygotes for p.S208T 
MEFV (III-2, III-3, IV-3), p=0.04 (figure 1C). Similar differ-
ences between groups were seen for circulating IL-18, p=0.01 
(figure 1D). Levels of IL-18 binding protein were not elevated 
compared with controls, p=0.28 suggesting a contribution to 
autoinflammation from free IL-18.
Caspase-1 activation, measured as the relative change 
in fluorochrome inhibitor of caspases (FLICA)+ cells after 
stimulation with lipopolysaccharide (LPS), was significantly 
elevated in patient CD14+cells compared with controls, 
p=0.001 and with p.S208T MEFV heterozygotes, p=0.01 
(figure 1E). Healthy control monocytes did not produce 
significantly increased levels of mature IL-1β in response to 
LPS likely because of the requirement of a second signal for 
inflammasome activation to allow cleavage of pro-IL-1β into 
the mature secreted form. Treatment of healthy control mono-
cytes with LPS and ATP to activate the NLRP3 inflammasome 
and TcdB (toxin B-positive Clostridium difficile), to activate 
the pyrin inflammasome, resulted in high levels of IL-1β secre-
tion. In contrast, patient monocytes demonstrated increased 
spontaneous inflammasome activation, because LPS alone was 
sufficient to induce an increase in IL-1β secretion compared 
with controls, p=0.001 (figure 1F). No significant difference 
in IL-1β secretion was observed between healthy and patient 
monocytes after ATP and TcdB addition or DNA stimulation, 
indicating similar maximal activities between the dephosphor-
ylated wild-type alleles and the S208T alleles (figure 1F and 
online supplementary figure 1A). A similar trend was shown 
for IL-18 release, p=0.03 and with no significant differences 
seen with addition of ATP and TcdB, p=0.21. In patient cells, 
there was also increased spontaneous ASC speck formation 
following treatment with LPS±TcdB compared with control 
cells.
PBMC with homozygous p.S208T MEFV treated with LPS 
or phorbol 12-myristate13-acetate (PMA)/ionomycin released 
increased levels of C-C-motif chemokine ligand 5 (CCL5), 
a potent chemotactic agent for recruitment of eosinophils 
(p=0.02 and p=0.001, respectively, for comparison with 
controls, figure 1G). There were no differences in circulating 
serum CCL-5between patients and controls (p=0.87) possibly 
as our patients had already received several therapies with 
normalisation of eosinophil counts at time of sampling.
Another individual, a 2-year-old boy of Pakistani consanguin-
eous descent (online supplementary figure 1B/C for pedigree 
and Sanger sequencing) was further identified with a homozy-
gous p.S208C (c.A622T) MEFV mutation. He presented with 
a similar phenotype to the above family characterised by recur-
rent fevers and elevated acute phase responses, oral ulceration 
(dense eosinophilic infiltration on histology), peripheral blood 
eosinophilia and osteitis.
This is the first report of human disease associated with 
mutant S208 MEFV, affecting the 14-3-3 protein binding 
domain of pyrin and leading to constitutive inflammasome 
activation.
Strong experimental evidence from both animal studies and 
mutant S208 pyrin transfection experiments in human cell 
lines indicates a crucial role of this residue for pyrin protein 
function, with specific clear impact of S208 mutated pyrin 
on loss of 14-3-3 binding previously documented.2 Previous 
studies have suggested that the S208 mutated pyrin has less of 
an effect on inflammasome activation compared with mutated 
S242R pyrin, indicating a functional hierarchy of importance 
between these two phosphorylation sites.4 This may partly 
explain the recessive mode of inheritance of autoinflammation 
associated with mutant S208 MEFV in contrast to heterozy-
gous mutant S242R MEFV.
Hypereosinophilia has not been described in previous 
reports of PAAND. S208 mutated, constitutively activated 
pyrin could result in secondary hypereosinophilia as a result 
of CCL5 production driving eosinophil chemotaxis and/or via 
primary activation of eosinophils expressing mutated pyrin.6 
IL-1 blockade may be a successful treatment for these patients 
and is being considered at the time of writing.
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